Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SLN · against 452 other Healthcare companies of similar size
Ranked #315 of 453 · scores higher than 9% of peers
Bars: peers in each 10-point band of the valuation score139 peers with a valuation score of 0–9, including SLN · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | SLN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 443 reported | -6.5% | 1.4% | 25% | 30% | |
| EBITDA yieldHigher is better · 456 reported | -7.4% | 4.3% | 19% | 50% | |
| Free cash flow yieldHigher is better · 205 reported | -3.4% | -1.6% | 43% | 20% | |
| Book yieldHigher is better · 448 reported | 4.1% | 40.9% | 7% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 1 | 14.8B MXN (≈$800M) | 99 | 61 | |
| 315 | 2.0B USD | 8 | 53 | |
| 315 | 1.2B USD | 8 | 40 | |
| 315 | 1.1B USD | 8 | 50 | |
| 315 | 673M USD | 8 | 35 | |
| 315 | 1.2B USD | 8 | 21 | |
| 315 | 1.3B USD | 8 | 33 | |
| 315 | 2.0B USD | 8 | 44 | |
| 315 | 1.7B USD | 8 | 30 | |
| 315 | 976M USD | 8 | 36 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score